Get the Stockscreener App
1.01
298.58%
0.7566
Polyrizon Ltd stock is traded at $1.01, with a volume of 352.80M.
It is up +298.58% in the last 24 hours and up +157.65% over the past month.
Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
See More
Previous Close:
$0.2534
Open:
$0.5232
24h Volume:
352.80M
Relative Volume:
61.96
Market Cap:
$13.54M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+197.06%
1M Performance:
+157.65%
6M Performance:
-13.68%
1Y Performance:
+0.00%
1-Day Range:
$0.5112
$1.19
1-Week Range:
$0.2472
$1.19
52-Week Range:
$0.2472
$4.80
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
1.01 | 13.54M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Polyrizon Ltd Stock (PLRZ) Latest News
United States shares higher at close of trade; Dow Jones Industrial Average up 1.39% - Investing.com India
Smart Digital Group And Polyrizon See Unusual Market Moves - Finimize
Nasdaq Surges Over 300 Points; Apple Shares Fall After Q2 Results - Benzinga
PLRZ Stock: Exploring Polyrizon Ltd’s Growth - investchronicle.com
Polyrizon (PLRZ) Stock Skyrocketed Over 240% Today: What's Going On? - Benzinga
PLRZ’s price-to-cash ratio: How it affects the stock’s valuation. - uspostnews.com
S&P 500 Gains 1%; April Jobs Top Expectations - Benzinga
Polyrizon Ltd (NASDAQ: PLRZ) Down -12.0% From 52-Week Low; YTD Falls -88.32% – Here’s What To Do Now - Marketing Sentinel
Why Twilio Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Polyrizon Ltd. Announces 1-for-10 Reverse Share Split Effective May 5, 2025 - TipRanks
Xylo Technologies: Revoltz Secures First Institutional Client for PORTO EV Logistics Deployment - The Manila Times
Press Release Distribution & PR Platform - ACCESS Newswire
PLRZ’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
How does PLRZ’s price to cash per share ratio compare in the market? - uspostnews.com
Polyrizon advances nasal allergy blocker safety study - Investing.com
Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model - The Manila Times
Polyrizon Achieves Milestone with Successful Safety Study of PL-14 - TipRanks
Polyrizon Ltd. Announces Successful Preliminary Safety Study for PL-14 Allergy Blocker Intranasal Hydrogel - Nasdaq
Breakthrough Safety Data: Polyrizon's 4-Hour Nasal Allergy Shield Passes Critical Human Tissue Test - Stock Titan
Polyrizon Ltd. Shareholders Approve Key Amendments at Annual Meeting - TipRanks
Polyrizon receives Nasdaq notification regarding minimum bid requirements - MSN
Polyrizon Faces Nasdaq Compliance Challenge - MSN
Polyrizon Gets Nasdaq Noncompliance Notice Over Minimum Bid Price Rule - marketscreener.com
Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements - marketscreener.com
Xylo subsidiary Revoltz launches PORTO EV in Israel - Investing.com Australia
Xylo Technologies: Revoltz Wins 2025 TAIPEI CYCLE Award for Micro-Mobility Innovation - The Manila Times
Polyrizon Raises $17 Million Through Private Placement to Advance Intranasal Hydrogel Technology - citybuzz -
Polyrizon Partners with Branding Firm for Strategic Brand Development - TipRanks
Polyrizon partners with branding firm for hydrogel tech - Investing.com
Polyrizon partners with branding firm for hydrogel tech By Investing.com - Investing.com Australia
Polyrizon Engages Leading Branding Firm for Strategic Brand Development - The Manila Times
Global Launch Preparations: Polyrizon's Game-Changing Virus Protection Technology Takes Major Step Forward - Stock Titan
Polyrizon raises $17 million in private placement By Investing.com - Investing.com South Africa
Polyrizon Ltd. Secures $17 Million in Private Placement to Advance Hydrogel Technology - TipRanks
Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement - The Manila Times
Polyrizon raises $17 million in private placement - Investing.com
Polyrizon Ltd. Announces Closing Of $17.0 Million Private Placement - MarketScreener
$17M Capital Injection: Inside Polyrizon's Latest Private Placement Deal Structure - Stock Titan
Polyrizon secures $17 million in private placement - Investing.com
Polyrizon Ltd. Announces $17.0 Million Private Placement - MarketScreener
Polyrizon Lands Major $17M Financing Deal: Inside the Strategic Investment Terms - Stock Titan
Polyrizon sets clinical strategy for allergy blocker By Investing.com - Investing.com Australia
Polyrizon Prepares Clinical Strategy for Allergy Blocker PL-14 - TipRanks
Polyrizon sets clinical strategy for allergy blocker - Investing.com
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting - The Manila Times
Polyrizon Structures Clinical Strategy For Its Allergy Blocker Ahead Of FDA Pre-Submission Meeting - MarketScreener
Breakthrough Nasal Allergy Treatment Takes Major Step Forward: Inside Polyrizon's FDA Strategy - Stock Titan
Polyrizon Ltd. Announces the Initiation of Preclinical Studies for Intranasal Benzodiazepines - Marketscreener.com
Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment - The Manila Times
Polyrizon begins preclinical studies for seizure treatment By Investing.com - Investing.com South Africa
Polyrizon begins BZDs studies for treating ARS and status epilepticus - TipRanks
Polyrizon Ltd Stock (PLRZ) Financials Data
There is no financial data for Polyrizon Ltd (PLRZ). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.47%
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):